Arovella Therapeutics, formerly SUDA Pharmaceuticals, is a former Perth-based, ASX-listed pharmaceutical company.
Originally focused solely on oro-mucosal drug delivery, the company changed its name to Arovella following the acquisition of the iNKT cell therapy platform for cancer treatment.
Its two focus areas are oncology and conditions that impact the central nervous system.